Individuals Discontinuing Anti-Obesity Injections Regain Pounds at a Quadrupled Rate Compared to Those on Conventional Diets

A recent study reveals that individuals who come off popular slimming jabs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who halt traditional lifestyle regimens.

Research printed in a leading health publication demonstrates that while obese people frequently drop about a fifth of their total mass while using the jabs, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.

"Individuals purchasing these drugs must be aware of the potential of fast rebound weight gain when the medication is stopped," cautioned researcher Dr. Susan Jebb.

That rate of regain suggests a return to pre-treatment mass within about a year and a half.

Comparing Therapies

The research, which looked at dozens of studies involving over 9,000 of patients, compared the effects of GLP-1 agonists with other pills.

The team emphasize that people who lose weight through dieting typically experience a more gradual creep back—around 100 grams monthly—after stopping.

Understanding the Rapid Rebound

Nutrition scientists suggest the way of the injections accounts for the accelerated regain.

GLP-1 drugs copy a body's own chemical called GLP-1, which helps regulate appetite.

"Sustained high doses of the hormone concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.

"Stopping of this GLP-1 'fix' means hunger is no longer kept in check, making binge eating far more likely."

An Ongoing Issue?

Health authorities suggest the jabs for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.

A number of clinicians contend that, due to the high risk of weight regain, the therapy should be considered ongoing.

This perspective is supported by pharmaceutical companies, who note that the findings "underscore the persistent nature of obesity," akin to managing diseases like hypertension.

Patient Experiences

People who have come off the jabs describe a intense resurgence of hunger.

"I experienced a trigger flipping and you become ravenous," described an individual.

This difficulty is exacerbated if individuals have not established lasting lifestyle or habit changes during therapy.

Widespread Adoption

Figures show that a significant number of adults in the UK have used these injections in the past year, with demand continuing to grow.

• Adoption is more common among females compared to men.
• The middle-aged demographic shows the highest level of interest.
• A large proportion obtain the medications through private healthcare rather than the NHS.

In conclusion, experts caution that while GLP-1 drugs are effective tools for weight loss, they are not a standalone cure and lasting health benefits relies on combined lifestyle changes.